-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $6.5

Benzinga·06/10/2026 12:36:19
Listen to the news
Chardan Capital analyst Keay Nakae initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Buy rating and announces Price Target of $6.5.